Onconase (P-30 Protein), an enzyme in the ribonuclease A superfamily, exerts cytostatic, cytotoxic and anti-viral activity when added to the media of growing mammalian cells. We find that onconase enters living mammalian cells and selectively cleaves tRNA with no detectable degradation of rRNA. The RNA specificity of onconase in vitro using reticulocyte lysate and purified RNA substrates indicates that proteins associated with rRNA protect the rRNA from the onconase ribonucleolytic action contributing to the cellular tRNA selectivity of onconase. The onconase-mediated tRNA degradation in cells appears to be accompanied by increased levels of tRNA turnover and induction of tRNA synthesis perhaps in response to the selective toxin-induced loss of tRNA.
INTRODUCTION
Onconase is a ribonuclease found in eggs and early embryos of the leopard frog (Rana pipiens) (1) . When incubated with mammalian cells in culture, the protein has cytotoxic and cytostatic acitiviy (2) unlike homologous mammalian members of the RNase A family. The protein expresses RNase activity that appears essential for its biological activities and is insensitive to inhibition by the ribonuclease inhibitor (RI) (1, 3, 4) . Resistance to RI is thought to explain the greater toxicity of onconase compared to mammalian members of the same RNase family (4) (5) (6) . Onconase consists of 104 amino acids, with a molecular mass of 11.8 Kd and an isoelectric point of 9.7 (1) . In contrast to mammalian RNase A family members including bovine pancreatic RNase, eosinophil-derived neurotoxin (EDN), and angiogenin (7, 8) the N-terminal pyroglutamyl residue, Pyr-1, is part of the active site, folding back against the N-terminal α-helix and forming a hydrogen bond with Val-96 in the C-terminal β-sheet (9).
Onconase displays anti-tumor activity in vivo (10, 11) , and is presently in phase III clinical trials. Onconase, at concentrations nontoxic to H9 cells, has been found to specifically inhibit HIV-1 replication in HIV-1 infected human H9 leukemia cells without necessarily killing the virus-infected cell (12, 13) . Examination of the mechanism of this inhibition reveals that onconase enters the infected cells and degrades HIV-1 RNA without degrading ribosomal RNA or the three different cellular messenger RNAs analyzed.
The primary molecular substrates and molecular mechanism of RNA selectivity for onconase anticancer and antiviral activity remain unclear. Here we describe the mechanism of a very specific elimination of tRNA and activation of tRNA synthesis by onconase in cells. oocytes by a modification of the previously published method (1). The enzyme was first isolated from the cell extract on SP-Sepharose, then further purified by rechromatography on the same exchanger followed by the size exclusion on Sephacryl S-100 in 75 mM ammonium bicarbonate and lyophilized. The final preparation was homogenous on SDS-PAGE and isoelectric focussing. Rabbit reticulocyte lysate (nuclease treated) was from Promega. All-trans retinoic acid was purchased from Calbiochem. CD4-positive H9 lymphocyte cells uninfected and persistently infected with HIV-1 IIIB strain were obtained from Dr. Robert Gallo, National Cancer Institute, NIH, Bethesda, MD. Purified E.coli 23S &16S ribosomal RNA and 5S ribosomal RNA were purchased from Boehringer Mannheim.
Purified tRNA Phe , and 0.1-1.0 kb RNA marker were purchased from Sigma.
DNA probes for detecting tRNA species. Three DNA oligonucleotide probes for detecting the tRNA Lys 3 , tRNA Lys 1,2 (14) and tRNA Phe (15) Cell pellets were processed to isolate total cellular RNA. Total RNA was analyzed on 1.4% agarose gel and 10% polyacrylamide gel containing 7.5 M urea.
Ribonuclease activity of onconase in 9L cells in the presence of retinoic acid. 9L (rat glioma) cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 2 mM glutamine, 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, and 10 µg/ml gentamycin (4). Retinoic acid stock solution (15 mM in dimethyl sulfoxide, DMSO) was diluted into leucine-free RPMI 1640 medium without fetal calf serum to 10 µM. The same dilution of DMSO was added in the control solutions. After removing the DMEM medium containing 10% fetal calf serum, cells were incubated in the above leucine-free RPMI 1640 medium containing increasing concentrations of onconase with or without retinoic acid for 20 h followed by isolation of total cellular RNA. Total RNA was analyzed on 1.4% agarose gel and 10% polyacrylamide gel containing 7.5 M urea.
Ribonuclease activity of onconase in rabbit reticulocyte lysate. RNA specificity of onconase was also tested in rabbit reticulocyte lysate using containing rabbit reticulocyte lysate and onconase at 1x10 -9 M to 1x10 -7 M concentrations were incubated for 15 minutes at 30°C. At the end of the incubation, the total RNA was isolated from the reaction mixture using RNAzol TM and the RNA pellet was dissolved in 10 mM Tris-HCl; pH 7.4 containing 1mM EDTA. ~1.5 µg of total RNA was analyzed in either 10% polyacrylamide gel containing 7.5 M urea or 1.4 % agarose gel. The RNA was visualized after staining the gel with ethidium bromide. In the experiment shown in Figure 3 , purified E. coli rRNA was added to the lysate and the onconase action studied.
Ribonuclease activity of onconase towards purified RNA from rabbit reticulocyte lysate. The reaction mixture (50 µl) containing purified RNA from rabbit reticulocyte lysate and onconase at 1x10 -9 M to 1x10 -7 M concentrations, were incubated for 15 minutes at 30°C, in PBS as reaction buffer. At the end of the incubation the total RNA from the reaction mixture was isolated using RNAzol TM .
The RNA pellet was dissolved in 10 mM Tris-HCl; pH 7.4 containing 1mM EDTA. Northern blot analysis. Northern blot analysis was carried out according to the protocols described (16) . Briefly ~1.5 µg of the total RNA from each set was denatured by heating at 70°C for 15 minutes in 1x formamide gel loading buffer (10% formamide/2mM EDTA/0.1% Xylene Cyanol/0.1% Bromophenol Blue), followed by a quick chill in icy water. The gel was pre-run for 30 minutes at 25 watts before loading the samples. These samples were electrophoresed on 10% polyacrylamide gel containing 7.5 M urea at 20 Watts for 2 h using 1X TBE (89 mM Tris/89 mM Borate/2 mM EDTA; pH 8.3) as a running buffer. After electrophoresis, the gel was fixed in 7% acetic acid for 30 minutes. The gel was photographed after staining with ethidium bromide in the 1X TBE for 10 minutes.
The gel was electro-blotted at 200 mA for 16 h onto Nytran Plus membranes (Schleicher & Schuell) using the 1X TBE as a running buffer. RNA was fixed onto filters by UV cross-linking (UV Stratalinker; Stratagene, LaJolla, CA). Prehybridization was carried out at 42°C for 6 h in the hybridization buffer [0.2% polyvinyl-pyrrolidone (MW 40,000), 0.2% ficoll (MW 400,000), 0.2% BSA, 0.05M Tris-HCl, pH 7.5, 1M sodium chloride, 0.1% sodium pyrophosphate, 1% SDS, 10% dextran sulfate (MW 500,000) and denatured salmon sperm DNA (0.1mg/ml)]. Following pre-hybridization, hybridization was carried out for 20 h at 42°C using the 32 P-5' end labeled ([γ-32 P]-ATP; DuPont, NEN; cat. # NEG-002Z) DNA probes for tRNA Lys 3 , tRNA Lys 1,2 (14) and tRNA Phe (15) . The Figure 1B ). This tRNA specificity is also observed when reticulocyte lysate is treated with onconase ( Figure 2A, lanes 2-4) . Specific tRNA degradation products (30-40 residues long) are visible even at 1x10 -9 M onconase concentration ( Figure 2A, lane 2 ). It appears that at least 10 fold higher concentrations of onconase are required outside cells to see tRNase activity inside the cells comparable to that in the reticulocyte lysate.
Onconase selectivity for tRNA species. When RNA from reticulocyte lysate is purified and incubated with onconase no selectivity for tRNA is seen (Figure 2A,   lanes 6-8) . In fact, rRNA, perhaps because of its large size, is more susceptible to rRNA in ribosomes (Figure 3 ). This is consistent with the model that the onconase specificity for tRNA seen in our experiments stems from the shielding of the substrate by associated proteins.
Potentiation of onconase cytotoxicity does not alter its RNA specificity.
Inside the cell, ribonucleases appear to route into the cytosol through the Golgi apparatus. Retinoic acid appears to disrupt the Golgi apparatus (17) and thus facilitates the transport of onconase into the cytosol. Onconase alone was shown to Figure 5B ) . The increased level of total tRNA Lys 3 continued through day 2 and 3 and fell back to control levels at day 4. Thus, as total tRNA levels stayed constant there appeared to be a mixture of tRNA degradation and stimulated tRNA synthesis to maintain constant total levels. A tRNA Lys 3 precursor band is also seen running above the tRNA Lys 3 band at days 2 and 3. In addition degraded forms of tRNA Lys 3 running at lower molecular weights can be seen as early as day 1 after onconase treatment, consistent with the model of onconase induced degradation and accelerated re-synthesis of tRNA. were incubated with a noncytotoxic concentration of onconase (5x10 -8 M) for one day followed by total RNA isolation using RNAzol. Total RNA was analyzed on
